Posted by Michael Wonder on 15 Sep 2021
Regeneron announces new U.S. Government agreement to purchase additional doses of REGEN-COV (casirivimab and imdemivab) antibody cocktail
14 September 2021 - New agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3 million doses.
Regeneron Pharmaceuticals today announced that the U.S. Department of Health and Human Services and the Department of Defense will purchase 1.4 million additional doses of REGEN-COV (casirivimab and imdevimab).
The government will continue to provide REGEN-COV at no cost to patients.
